IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v13y2012i5p561-568.html
   My bibliography  Save this article

Disease progression and costs of care in Alzheimer’s disease patients treated with donepezil: a longitudinal naturalistic cohort

Author

Listed:
  • Anders Gustavsson
  • Linus Jönsson
  • Johan Parmler
  • Niels Andreasen
  • Carina Wattmo
  • Åsa Wallin
  • Lennart Minthon

Abstract

The proposed methods for representing AD progression and economic outcomes can be used in micro-simulation models for the economic evaluation of new treatments. Copyright Springer-Verlag 2012

Suggested Citation

  • Anders Gustavsson & Linus Jönsson & Johan Parmler & Niels Andreasen & Carina Wattmo & Åsa Wallin & Lennart Minthon, 2012. "Disease progression and costs of care in Alzheimer’s disease patients treated with donepezil: a longitudinal naturalistic cohort," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(5), pages 561-568, October.
  • Handle: RePEc:spr:eujhec:v:13:y:2012:i:5:p:561-568
    DOI: 10.1007/s10198-011-0334-y
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1007/s10198-011-0334-y
    Download Restriction: Access to full text is restricted to subscribers.

    File URL: https://libkey.io/10.1007/s10198-011-0334-y?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Ansgar Wübker & Sandra Zwakhalen & David Challis & Riitta Suhonen & Staffan Karlsson & Adelaida Zabalegui & Maria Soto & Kai Saks & Dirk Sauerland, 2015. "Costs of care for people with dementia just before and after nursing home placement: primary data from eight European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(7), pages 689-707, September.

    More about this item

    Keywords

    Alzheimer’s disease; Cost of care; Economic modeling; Institutionalization; Cholinesterase inhibitors; Long-term; ADL; Cognition; I19 - Health other;
    All these keywords.

    JEL classification:

    • I19 - Health, Education, and Welfare - - Health - - - Other

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:13:y:2012:i:5:p:561-568. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.